Dynamic Strategy and Disruptive Innovation for Radiopharmaceuticals

Dynamic Strategy and
Disruptive Innovation
SLIDE 1

2
INTERNAL PERSPECTIVE
Dynamic Strategy and Disruptive
Innovation
Radiopharmaceuticals
• In general, the standards for preparing the
Radiopharmaceuticals can be summarised under the
regulations of GMP in the country.
• There are other specific regulations related to issuing of
specific drugs and regarding sterility testing which is a specific
component that needs to be maintained for rapid
development of Radiopharmaceuticals.
• The organisation FutureMed is primarily associated with the
production of PET and radionuclide production.
• In this context, the organisation enjoys an added advantage
that there is a highly vigilant team of senior managers.
• However, the organisation lacks the systematic approach that
is needed for the identification of the possibilities of creation
of new medicines of different category
• As an outcome, in the recent future the organisation might
reach a state of market saturation.
• Again, as identified by Teece, Peteraf and Leih (2016), the
organisations that are involved with the production of
futuristic health care technologies and disruptive medicinal
solutions should be employing a clinical research method also.

3
RECOMMENDATIONS
Dynamic Strategy and Disruptive
Innovation
• As identified in the research case study it
can be highlighted that there is lack of a
systematic approach in the organisation
• A systematic approach is essential in this
context because of the fact that since the
organisation is dealing in a business that
aims at finding a futuristic solution
based on nuclear technology, the
identification or the development of
potential disruptive technologies is very
necessary

4
CONTINUED...
Dynamic Strategy and Disruptive
Innovation
• Slow operations or lack of systematic approach will not
let the organisation to introduce a new invention in the
market easily, even if they have a full proven formulation
and blue orient for the same.
• This is because of several critical factors that the higher
management and the board of directors also needs to
consider.
• These are very minute factors, however very essential for
the development of new formulations in the filed of
disruptive medicinal technologies
• The first is the need for clean room facilities where the
laser cleaning technology needs to be implanted for
annihilation of reactive agents and germs.
• In any organisation, there are mostly some third party
agencies that are associated with the maintenance of the
labs for chemical testing and research of new medicines.